NCT05008939

Sevoflurane for Treatment-Resistant Depression

Subanesthetic Sevoflurane for Treatment-Resistant Depression: A Proof-of-Concept Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Shanghai First Maternity and Infant Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.

Conditions

• Depressive Disorder, Treatment-Resistant
• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	Sevoflurane	Patients receive 1% sevoflurane and 30% oxygen for 1 hour.
DRUG	Placebo	Patients received 30% oxygen for 1 hour.

Timeline

• Start date: 2021-08-01
• Primary completion: 2022-03-01
• Completion: 2022-03-01
• First posted: 2021-08-17
• Last updated: 2021-08-17

Locations

1 site across 1 country: China